Galena Biopharma (GALE)

Add to Watchlists
Create an Alert
0.4202 +0.01  +1.30% NASDAQ Aug 26, 20:00 Delayed 2m USD

Galena Biopharma Balance Sheet (Quarterly)

Export Data

March 2016 - December 2013

Previous Periods

Assets (Quarterly) 2016-03 2015-12 2015-09 2015-06 2015-03 2014-12 2014-09 2014-06 2014-03 2013-12
Cash and Equivalents Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Short Term Investments Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Cash and Short Term Investments 34.71M 29.73M 34.81M 45.28M 52.86M 23.65M 24.65M 39.16M 52.43M 47.79M
Accounts Receivable 1.818M 1.060M 1.435M 2.152M 1.466M 3.683M
Total Receivables Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Inventories 1.426M 0.6370M 0.4500M 0.4330M 0.3580M 0.3860M
Prepaid Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Restricted Cash Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Current Assets Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Current Assets Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Machine, Furniture & Equipment Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Gross PP&E Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Accumulated D&A Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net PP&E 0.2990M 0.3350M 0.2880M 0.5320M 0.5280M 0.2850M 0.5890M 0.6230M 0.6530M 0.6650M
Goodwill Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Intangible Assets Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Goodwill and Intangibles Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Long Term Investments Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Long Term Assets Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Long Term Assets Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Assets 66.36M 82.14M 82.67M 101.97M 108.61M 80.49M 79.49M 80.28M 92.29M 87.98M
Liabilities (Quarterly) 2016-03 2015-12 2015-09 2015-06 2015-03 2014-12 2014-09 2014-06 2014-03 2013-12
Accounts Payable 1.019M 1.597M 1.238M 2.318M 3.293M 1.886M 3.360M 2.036M 1.574M 2.660M
Current Tax Payable Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Payables Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Payables Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Accrued Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Payables and Accrued Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Notes Payable Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Current Portion of Long Term Debt Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Current Capital Lease Obligation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Current Debt & Capital Lease Obligation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Current Deferred Revenue Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Current Deferred Liabilities Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Current Liability Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Current Liabilities Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Current Portion of Long Term Debt Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Long Term Cap Lease Obligation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Current Portion of LTD and Capital Lease Obligation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Long Term Deferred Tax Liabilities Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Current Deferred Liabilities Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Long Term Liabilities Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Long Term Liabilities Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Liabilities 53.95M 68.63M 50.25M 52.60M 49.52M 43.43M 48.63M 51.97M 45.79M 82.09M
Shareholder's Equity (Quarterly) 2016-03 2015-12 2015-09 2015-06 2015-03 2014-12 2014-09 2014-06 2014-03 2013-12
Total Capital Stock Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Retained Earnings -295.88M -279.38M -259.70M -241.68M -226.02M -215.48M -207.53M -201.35M -181.41M -178.88M
Additional Paid In Capital Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Treasury Stock Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Accrued Comprehensive Inc Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Shareholders Equity 12.41M 13.51M 32.42M 49.37M 59.08M 37.06M 30.86M 28.31M 46.50M 5.886M
SEC Filing Links 2016-03 2015-12 2015-09 2015-06 2015-03 2014-12 2014-09 2014-06 2014-03 2013-12
As Originally Reported AOR AOR AOR AOR AOR AOR AOR AOR AOR AOR
Restated Restated Restated Restated Restated Restated Restated Restated

March 2016 - December 2013

Previous Periods

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 7-Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.